Genomic test to rule out obstructive CAD may reduce need for more invasive diagnostics

©2014 Mary Ann Liebert, Inc., publishers

Nearly $7 billion is spent each year in the U.S. on diagnostic testing of the estimated three million people with symptoms of obstructive coronary artery disease (CAD). A new blood test that detects specific genes activated in individuals with obstructive CAD could exclude the diagnosis without the need for imaging studies or more invasive tests, reducing health care costs, as described in an article in Population Health Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Louis Hochheiser (St. John's Medical Center, Jackson, WY), Jessie Juusola and Mark Monane (CardioDx, Palo Alto, CA), and Joseph Ladapo (New York University School of Medicine, NY), use a decision analysis model to compare the cost-effectiveness of "usual care" for obstructive CAD diagnosis with a strategy that includes "gene expression score (GES)-directed care." They present the results and potential value of this new diagnostic approach in the article "Economic Utility of a Blood-Based Genomic Test for the Assessment of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease".

"Work like this is vital to our understanding as we move from a world of volume to value," says Editor-in-Chief David B. Nash, MD, MBA, Dean and Dr. Raymond C. and Doris N. Grandon Professor, Jefferson School of Population Health, Philadelphia, PA.

More information: The article is available free on the Population Health Management website at http://www.liebertpub.com/pop.

add to favorites email to friend print save as pdf

Related Stories

Undiagnosed diabetes takes economic toll

May 07, 2009

Approximately 6.3 million adults—or one fourth of the people in the U.S. with diabetes mellitus—are unaware they have the disease, and this undiagnosed population accounts for an estimated $18 billion in health care costs ...

Recommended for you

Correction of cardiovascular symptoms of MPS I in animal model

57 minutes ago

REGENXBIO Inc. today announced that gene transfer mediated by REGENXBIO's NAV AAV8 vectors resulted in sustained serum α-L-iduronidase (IDUA) expression, as well as correction of systemic features of MPS I, or Hurler syndrome, ...

Researchers explain 38-year-old mystery of the heart

14 hours ago

In a new study published in Proceedings of the National Academy of Sciences, researchers at the University of Alberta's Faculty of Medicine & Dentistry have explained how the function of a key protein in the ...

User comments